




## Supplemental Material



**Supplemental Figure S1.** Binding and neutralizing antibodies to VOCs in PARVAX boosted and not boosted non-human primates. **A-D)** Binding antibody responses (AU/mL) in boosted and not boosted animals against Wuhan (A), Alpha (B), Beta (C) and Delta (D) on week 15 (pre-boost), week 24 (9 weeks post-boost) and week 28 (13 weeks post-boost). **E-G)** Wuhan (E), Beta (F) and Delta (G) neutralizing antibody responses on week 15 (pre-boost), week 19 (4 weeks post-boost) and week 24 (9 weeks post-boost).



**Supplemental Figure S2.** Longitudinal antibody responses in PARVAX boosted and not boosted non-human primates. **A-C** Longitudinal Wuhan (A), Beta (B) and Delta (C) binding antibody (AU/mL) responses up to week 48 after prime (ACM-Delta) administration. **D-F** Longitudinal Wuhan (D), Beta (E) and Delta (F) neutralizing antibody responses up to week 48 after prime administration. Arrows indicate timing of second PARVAX administration (ACM-BA.1 or Saline).



**Supplemental Figure S3.** Cellular immune responses in PARVAX boosted and not boosted non-human primates.. **A-B)** IFN-gamma spot forming cells (SFC) after Wuhan (A) or Delta (B) Spike protein peptide stimulation of peripheral blood mononuclear cells (PBMC) extracted on week 15 (pre-boost), week 19 (4 weeks post-boost), week 24 (9 weeks post-boost) and week 28 (13 weeks post-boost).